ArticleMalaria journal2012
Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.
Article in Malaria journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Beyond the mouse: organoids, spheroids, and organs-on-chips as the (inevitable) future of malaria research?Malaria journal · 2026Review
- Pathogenetic mechanisms and treatment targets in cerebral malaria.Nature reviews. Neurology · 2023Review
- Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model.Pharmaceutics · 2022Article
- Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria.Pathogens (Basel, Switzerland) · 2022Article
- Cerebral malaria induced byFrontiers in cellular and infection microbiology · 2022Review
- Targeting liver stage malaria with metformin.JCI insight · 2019Article
- Statins: a viable candidate for host-directed therapy against infectious diseases.Nature reviews. Immunology · 2019Review
- Atorvastatin DownregulatesOxidative medicine and cellular longevity · 2018Article
- Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.PloS one · 2018Article
- Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.Annals of translational medicine · 2016Review
- Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection.Parasitology research · 2016Article
- Review
- Simultaneously targeting inflammatory response and parasite sequestration in brain to treat Experimental Cerebral Malaria.Scientific reports · 2015Article
- In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum.Malaria journal · 2014Article
- Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.Malaria journal · 2013Article
- Contrasting pediatric and adult cerebral malaria: the role of the endothelial barrier.Virulence · 2013Review
- Dose responses of proveblue methylene blue in an experimental murine cerebral malaria model.Antimicrobial agents and chemotherapy · 2013Article
- Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.Malaria journal · 2013Article
- Article
- Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria.PLoS pathogens · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the major complications of Plasmodium falciparum infection is cerebral malaria (CM), which causes one million deaths worldwide each year, results in long-term neurological sequelae and the treatment for which is only partially effective. Statins are recognized to have an immunomodulatory action, attenuate sepsis and have a neuroprotective effect. Atorvastatin (AVA) has shown in vitro anti-malarial activity and has improved the activity of mefloquine (MQ) and quinine.
methodsThe efficiency of 40 mg/kg intraperitoneal AVA, alone or in association with MQ, was assessed in an experimental Plasmodium berghei ANKA rodent parasite model of CM and performed according to different therapeutic schemes. The effects on experimental CM were assessed through the evaluation of brain histopathological changes and neuronal apoptosis by TUNEL staining.
resultsAVA alone in the therapeutic scheme show no effect on survival, but the prophylactic scheme employing AVA associated with MQ, rather than MQ alone, led to a significant delay in mouse death and had an effect on the onset of CM symptoms and on the level of parasitaemia. Histopathological findings show a correlation between brain lesions and CM onset. A neuronal anti-apoptotic effect of AVA in the AVA + MQ combination was not shown.
conclusionsThe combination of AVA and MQ therapy led to a significant delay in mouse mortality. There were differences in the incidence, time to cerebral malaria and the level of parasitaemia when the drug combination was administered to mice. When used in combination with MQ, AVA had a relevant effect on the in vivo growth inhibition and clinical outcome of P. berghei ANKA-infected mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.